Boundless Bio, Inc. Common Stock (BOLD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Boundless Bio, Inc. Common Stock (BOLD) has a cash flow conversion efficiency ratio of -0.093x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-10.20 Million) by net assets ($110.17 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see BOLD market cap for the company's overall valuation and market capitalisation.
Boundless Bio, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Boundless Bio, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Boundless Bio, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Boundless Bio, Inc. Common Stock ranked by their cash flow conversion efficiency. See debt repayment capacity of Boundless Bio, Inc. Common Stock to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Gaia Inc
NASDAQ:GAIA
|
-0.055x |
|
Trend Gayrimenkul Yatirim Ortakligi AS
IS:TDGYO
|
0.222x |
|
Shenzhen Textile Holdings Co Ltd
SHE:200045
|
0.012x |
|
Champion Pacific Indonesia Tbk
JK:IGAR
|
0.005x |
|
LMS Co. Ltd
KQ:073110
|
-0.071x |
|
Pamapol S.A.
WAR:PMP
|
-0.041x |
|
Ovaro Kiinteistosijoitus Oyj
HE:OVARO
|
-0.048x |
|
Sin-Kung Logistics Berhad
KLSE:0305
|
0.042x |
Annual Cash Flow Conversion Efficiency for Boundless Bio, Inc. Common Stock (2016–2024)
The table below shows the annual cash flow conversion efficiency of Boundless Bio, Inc. Common Stock from 2016 to 2024. View current stock price of Boundless Bio, Inc. Common Stock for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $150.64 Million | $-60.84 Million | -0.404x | -209.54% |
| 2023-12-31 | $-127.08 Million | $-46.85 Million | 0.369x | -23.93% |
| 2022-12-31 | $-81.70 Million | $-39.60 Million | 0.485x | -20.38% |
| 2021-12-31 | $-38.19 Million | $-23.25 Million | 0.609x | +349.62% |
| 2018-12-31 | $442.75 Million | $-107.98 Million | -0.244x | +54.81% |
| 2017-12-31 | $156.60 Million | $-84.51 Million | -0.540x | -31.42% |
| 2016-12-31 | $119.37 Million | $-49.02 Million | -0.411x | -- |
About Boundless Bio, Inc. Common Stock
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA). The company's lead product candidate is BBI-355, an ecDNA-directed therapeutic candidate and oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene ampli… Read more